Leading innovation in the 21st century, the future of imaging diagnosis drawn by Nanoox

[의학신문·일간보사=오인규 기자] Imaging diagnosis, a basic field of modern medicine. However, many experts say that a game-changing ‘groundbreaking change’ is needed in a reality that is suffering from shortages in all aspects, including devices, accessibility, high cost, and radiologists.

Nanoox, which appeared with a grand ambition to overcome this, not only innovates the imaging field in terms of accessibility and economy, but also strengthens imaging capabilities at major hospitals using conventional X-ray equipment and CT scanners, and as a result, the standard He said he was determined to strengthen treatment.

Yozma Group Korea held a meeting with the medical device industry professional reporters on the 14th to raise awareness of the innovative technology and clinical benefits of Nanox, an investment company.

The meeting was held on this day △Introduction of Nanox’s innovative technology (Dr. Amir Ben-Shalom, former CSO of Nanox) △Interpretation of lesioned chest diagnostic image (Dr. Dr. Wimpheimer, CMO of Nanox), etc.

Combining innovative cold cathode technology with MSaaS business model

Nanox Arc product image

First, Nanox developed a small, lightweight and inexpensive scanning device called Nanox ARC, and introduced the idea of ​​Service Medical Imaging Software (MSaaS) to improve the accessibility and economic feasibility of early detection services worldwide.

Utilizing a new digital microelectromechanical system (MEMS), the Nanox Arc is a fixed X-ray system designed to tomography and capture body parts in patients and examinations of various sizes with a single tomography. Tilt and divert the tube along the spherical shell path.

The existing tube consists of a hot cathode. It was hot and expensive as the filament had to be heated to 2000 degrees Celsius before releasing electrons that were conjugated on the rotating anode.

On the other hand, Nanoox is using a semiconductor-based cold cathode. There are hundreds of millions of tiny cones in its own semiconductor, each capable of emitting one electron. The emitted electrons are controlled digitally without mechanics, and operate in conjunction with the anode with high efficiency. As a core technology, it is evaluated that it can be produced at a lower cost than competing medical imaging systems and has the same performance as the existing X-ray analog cathode.

Multi-morality that Nanoox is paying attention to as an advantage<br />” src=”<a data-ail=news/photo/202201/2166608_198056_4442.jpg”/>
Multi-morality that Nanoox is paying attention to as an advantage

Thanks to its unique MSaaS business model, along with its proprietary and innovative cold cathode technology, it has a solution that can make the most of the market needs in terms of cost and accessibility, out-of-hospital imaging, cloud-based technology, and more.

Providing health care providers with Nanox Arc free of charge or at a minimal cost, removing the barrier to significant upfront capital expenditure, and enabling all communities to receive life-saving medical screening.

Yozma Group is confident that “Nanoox has its own unique technology and business approach, and holds the key to solving medical problems and realizing innovations in the 21st century in the field of imaging.”

Selected Korea as a production base for Nanox arc core parts

Meanwhile, it continues to invest in the domestic market. Nanox will use 40 million dollars (about 44.4 billion won) in Korea to build a permanent factory on a 12,000 square meter site purchased earlier this year near the Yongin SK Hynix semiconductor cluster and start operation in the first half of 2022.

Nanox has selected Korea as a production base for MEMS semiconductor chips and tubes, which are core components of Nanox Arc, and all temporary production facilities in Cheongju will be relocated once the construction of the Yongin plant is completed. It is planned to increase the semiconductor chip production capacity and expand the clean room size for semiconductor production to more than three times that of the existing Cheongju plant. 100% of MEMS chip production is done through the Korean production line.

It develops and manufactures X-ray tubes for Nanox arc systems using its unique low-temperature emitter technology made from MEMS chips. System assembly for pre-production will take place in Israel and will be expanded at the end of 2021 and in the first quarter of 2022. Among them, Korea, Taiwan, and India are mentioned as candidates.

Erez Melcher, CEO of Nanox, who participated in this web meeting<사진>“Our medical imaging system will be key to expanding early diagnosis and improving patient care.” will be expanded,” he said.

He said, “We plan to comply with regulatory requirements in all regions where we plan to do business, and Korea is particularly well-received for medical-related know-how, expertise, and pursuit of perfection.” I am sure they will be a great partner.”




Leave a Reply

Your email address will not be published.